- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04396860
Testen van het gebruik van de geneesmiddelen voor immunotherapie Ipilimumab en Nivolumab Plus bestralingstherapie in vergelijking met de gebruikelijke behandeling (temozolomide en bestralingstherapie) voor nieuw gediagnosticeerd MGMT ongemethyleerd glioblastoom
Een gerandomiseerde fase II/III open-label studie van ipilimumab en nivolumab versus temozolomide bij patiënten met nieuw gediagnosticeerde MGMT (tumor O-6-methylguanine DNA-methyltransferase) niet-gemethyleerd glioblastoom
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Verenigde Staten, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Verenigde Staten, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Verenigde Staten, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Verenigde Staten, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Verenigde Staten, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Verenigde Staten, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Verenigde Staten, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Verenigde Staten, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Verenigde Staten, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Verenigde Staten, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Verenigde Staten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Verenigde Staten, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Verenigde Staten, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Verenigde Staten, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Verenigde Staten, 80210
- AdventHealth Porter
-
Littleton, Colorado, Verenigde Staten, 80122
- AdventHealth Littleton
-
Parker, Colorado, Verenigde Staten, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06102
- Hartford Hospital
-
New Britain, Connecticut, Verenigde Staten, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Verenigde Staten, 19958
- Beebe Medical Center
-
Millville, Delaware, Verenigde Staten, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Verenigde Staten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Verenigde Staten, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Verenigde Staten, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Verenigde Staten, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Verenigde Staten, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Verenigde Staten, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Verenigde Staten, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Verenigde Staten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Verenigde Staten, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Verenigde Staten, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Verenigde Staten, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Verenigde Staten, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Verenigde Staten, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Verenigde Staten, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Verenigde Staten, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Verenigde Staten, 96813
- Island Urology
-
Kailua, Hawaii, Verenigde Staten, 96734
- Castle Medical Center
-
Lihue, Hawaii, Verenigde Staten, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Verenigde Staten, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Verenigde Staten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Verenigde Staten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Verenigde Staten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Verenigde Staten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Verenigde Staten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Verenigde Staten, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Verenigde Staten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Verenigde Staten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Danville, Illinois, Verenigde Staten, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Verenigde Staten, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Verenigde Staten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Verenigde Staten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Verenigde Staten, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Verenigde Staten, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Verenigde Staten, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Verenigde Staten, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Verenigde Staten, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Verenigde Staten, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Verenigde Staten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Verenigde Staten, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Verenigde Staten, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Verenigde Staten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Verenigde Staten, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Verenigde Staten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Verenigde Staten, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Verenigde Staten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Verenigde Staten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Verenigde Staten, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Verenigde Staten, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Verenigde Staten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Verenigde Staten, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Verenigde Staten, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Verenigde Staten, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Verenigde Staten, 62702
- Springfield Clinic
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
Urbana, Illinois, Verenigde Staten, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Verenigde Staten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Verenigde Staten, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Verenigde Staten, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Verenigde Staten, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Verenigde Staten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Verenigde Staten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Verenigde Staten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Verenigde Staten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Verenigde Staten, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Verenigde Staten, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Verenigde Staten, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Verenigde Staten, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Verenigde Staten, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Verenigde Staten, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Verenigde Staten, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Verenigde Staten, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Verenigde Staten, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Verenigde Staten, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Verenigde Staten, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Verenigde Staten, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Verenigde Staten, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Verenigde Staten, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Verenigde Staten, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Verenigde Staten, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Verenigde Staten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Verenigde Staten, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Verenigde Staten, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Verenigde Staten, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Verenigde Staten, 48503
- Hurley Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Verenigde Staten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Verenigde Staten, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Verenigde Staten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Verenigde Staten, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Verenigde Staten, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Verenigde Staten, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Verenigde Staten, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Verenigde Staten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Verenigde Staten, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Verenigde Staten, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Mercy Hospital
-
Edina, Minnesota, Verenigde Staten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Verenigde Staten, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Verenigde Staten, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Verenigde Staten, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- United Hospital
-
Stillwater, Minnesota, Verenigde Staten, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Verenigde Staten, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Verenigde Staten, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Verenigde Staten, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Verenigde Staten, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Verenigde Staten, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Verenigde Staten, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Verenigde Staten, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Verenigde Staten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Verenigde Staten, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Verenigde Staten, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Verenigde Staten, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Verenigde Staten, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Verenigde Staten, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Verenigde Staten, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Verenigde Staten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Verenigde Staten, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Verenigde Staten, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Verenigde Staten, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Verenigde Staten, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Verenigde Staten, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Verenigde Staten, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Verenigde Staten, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Verenigde Staten, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Verenigde Staten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Verenigde Staten, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Verenigde Staten, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Verenigde Staten, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Verenigde Staten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Verenigde Staten, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Verenigde Staten, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Verenigde Staten, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Verenigde Staten, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Verenigde Staten, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Verenigde Staten, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Verenigde Staten, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Verenigde Staten, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Verenigde Staten, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Verenigde Staten, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Verenigde Staten, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Verenigde Staten, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Verenigde Staten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Verenigde Staten, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Verenigde Staten, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Verenigde Staten, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Verenigde Staten, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Verenigde Staten, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Verenigde Staten, 84321
- Logan Regional Hospital
-
Murray, Utah, Verenigde Staten, 84107
- Intermountain Medical Center
-
Ogden, Utah, Verenigde Staten, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Verenigde Staten, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Verenigde Staten, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Verenigde Staten, 84143
- LDS Hospital
-
St. George, Utah, Verenigde Staten, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Verenigde Staten, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Verenigde Staten, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Verenigde Staten, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Verenigde Staten, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Verenigde Staten, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Verenigde Staten, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Verenigde Staten, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Verenigde Staten, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Verenigde Staten, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Verenigde Staten, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Verenigde Staten, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Verenigde Staten, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Verenigde Staten, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Verenigde Staten, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Verenigde Staten, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Verenigde Staten, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Verenigde Staten, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Verenigde Staten, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Verenigde Staten, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Verenigde Staten, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Verenigde Staten, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Verenigde Staten, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Verenigde Staten, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Verenigde Staten, 53227
- Aurora West Allis Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andere namen:
Ancillary studies Given PO
Andere namen:
Undergo radiation therapy
Andere namen:
Undergo contrast-enhanced brain MRI
Andere namen:
Wear Optune device
Andere namen:
|
|
Experimenteel: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andere namen:
Given IV
Andere namen:
Ancillary studies Given IV
Andere namen:
Undergo radiation therapy
Andere namen:
Undergo contrast-enhanced brain MRI
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Tijdsspanne: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Tijdsspanne: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Tijdsspanne: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Tijdsspanne: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Tijdsspanne: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Tijdsspanne: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Tijdsspanne: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Tijdsspanne: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
OS (als de studie wordt stopgezet in fase II)
Tijdsspanne: Aan het einde van fase II van de studie
|
Aan het einde van fase II van de studie
|
|
|
Tumor Biomarker Analyses
Tijdsspanne: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Tijdsspanne: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Andrew B Lassman, NRG Oncology
Publicaties en nuttige links
Algemene publicaties
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Glioom
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Gliosarcoom
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Onderzoekstechnieken
- Therapeutica
- Azoles
- Farmacologische acties
- Chemische acties en gebruik
- Biologische factoren
- Fysieke fenomeen
- Dacarbazine
- Triazenen
- Imidazolen
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Specialiteitgebruik van chemicaliën
- Chemie -technieken, analytisch
- Spectrumanalyse
- Receptoren, celoppervlak
- Membraaneiwitten
- Antigenen
- Antigenen, oppervlak
- Biomarkers
- Diagnostisch gebruik van chemicaliën
- Receptoren, immunologisch
- Antigenen, differentiatie, T-lymfocyt
- Antigenen, differentiatie
- Immuun checkpoint -eiwitten
- Costimulatoire en remmende T-celreceptoren
- Temozolomide
- Nivolumab
- Ipilimumab
- Radiotherapie
- Bestraling
- Magnetische resonantiespectroscopie
- Contrast media
- CTLA-4 antigeen
Andere studie-ID-nummers
- NCI-2020-03404
- U10CA180868 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2020-03404 (Register-ID: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Andere identificatie: CTEP)
- NRG-BN007 (Andere identificatie: NRG Oncology)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .